Table 2 Summary of clinical outcomes for patients receiving total doses of ≥ 66 Gy vs. < 66 Gy in an Equivalent dose in 2-Gy fractions.

From: Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy

Dose group

Event

6y-bRFS

p-value

Event

6y-cRFS

p-value

Event

6y-CSS

p-value

Event

6y-OS

p-value

 ≥ 66 Gy (n = 226)

95 (42%)

56 (49–62)

0.21

12 (5%)

94 (90–97)

0.022

0

100

 < 0.001

11 (5%)

96 (92–98)

0.006

 < 66 Gy (n = 66)

23 (35%)

66 (52–76)

10 (15%)

87 (75–93)

6 (9%)

91 (79–96)

14 (21%)

86 (74–93)

Total (n = 292)

118 (40%)

58 (52–64)

22 (8%)

92 (88–95)

6 (2%)

98 (95–99)

25 (8%)

94 (90–96)

  1. Data are n (%) or % (95% confidence interval).
  2. bRFS biochemical relapse-free survival, cRFS clinical relapse-free survival, CSS cancer-specific survival, OS overall survival.
Back to article page